-
公开(公告)号：US11773145B2
公开(公告)日：2023-10-03
申请号：US16632299
申请日：2018-07-20
Applicant: ShanghaiTech University
Inventor： Jia Liu , Biao Jiang
CPC classification number: C07K14/33 , C07K19/00 , A61K38/00 , C07K2319/55 , C07K2319/81
Abstract: Provided are chimeric polypeptides that include one or more zinc finger motifs fused to a therapeutic peptide such as botulinum neurotoxins (BoNTs). The zinc finger motif may be located at the C-terminal side of the BoNT and the chimeric polypeptide can optionally include two or more such zinc finger motifs. It said the disclosed chimeric polypeptides can be efficiently delivered to a subject transdermally.
-
公开(公告)号：US20210317480A1
公开(公告)日：2021-10-14
申请号：US17272252
申请日：2019-08-29
Applicant: ShanghaiTech University
Inventor： Jia Liu , Biao Jiang , Peixiang Ma , Guang Yang
Abstract: Provided are amino acid sequences capable of binding to and inhibiting a Cas protein's ability to bind to a nucleic acid molecule, thereby inhibiting the Cas protein's function in genome editing. Such Cas protein inhibitors, which can be comprised of a major coat protein (G8P), an extracellular region of the G8P (G8PEX), or a biological equivalent, are useful in improving the specificity of Cas protein-based genome editing procedures.
-
公开(公告)号：US20240018196A1
公开(公告)日：2024-01-18
申请号：US18451700
申请日：2023-08-17
Applicant: ShanghaiTech University
Inventor： Jia Liu , Biao Jiang
Abstract: The present disclosure provides chimeric polypeptides that include one or more zinc finger motif fused to a therapeutic peptide such as botulinum neurotoxins (BoNTs). The zinc finger motif may be located at the C-terminal side of the BoNT and the chimeric polypeptide can optionally include two or more such zinc finger motifs. It is shown that the disclosed chimeric polypeptides can be efficiently delivered to a subject transdermally.
-
公开(公告)号：US11771709B2
公开(公告)日：2023-10-03
申请号：US16902172
申请日：2020-06-15
Applicant: ShanghaiTech University
Inventor： Xiaobao Yang , Biao Jiang , Xiaoling Song , Haifan Lin , Ning Sun , Jinju Chen , Xing Qiu , Chaowei Ren , Ying Kong
IPC: A61K31/662 , A61P35/00 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/519 , A61K45/06
CPC classification number: A61K31/662 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/519 , A61P35/00 , A61K45/06
Abstract: A compound of formula (I) and its antitumor application are disclosed. The compounds of formula (I) have degradation and inhibitory effects on ALK target proteins. They are mainly composed of four parts: the first part, ALK-TKI, being compounds with ALK tyrosine kinase inhibitory activity; the second part, LIN, being different kinds of linker (Linker); the third part, the ULM, being a small molecule ligand (ULM, ubiquitin ligase binding moiety) with ubiquitination of VHL, CRBN or other proteases; and the fourth part, the group A, being a carbonyl group or absent, which covalently bond ALK-TKI to LIN, wherein LIN and ULM are covalently bonded. A series of compounds designed and synthesized by the present disclosure have wide pharmacological activities, have functions of degrading ALK protein and inhibiting ALK activity, and can be used for related tumor treatment.
-
公开(公告)号：US20200231634A1
公开(公告)日：2020-07-23
申请号：US16632299
申请日：2018-07-20
Applicant: ShanghaiTech University
Inventor： Jia Liu , Biao Jiang
Abstract: Provided are chimeric polypeptides that include one or more zinc finger motifs fused to a therapeutic peptide such as botulinum neurotoxins (BoNTs). The zinc finger motif may be located at the C-terminal side of the BoNT and the chimeric polypeptide can optionally include two or more such zinc finger motifs. It said the disclosed chimeric polypeptides can be efficiently delivered to a subject transdermally.
-
Patent Agency Ranking
公开(公告)号：US12226424B2
公开(公告)日：2025-02-18
申请号：US17046690
申请日：2019-04-09
Applicant: ShanghaiTech University
Inventor： Xiaobao Yang , Biao Jiang , Renhong Sun , Chaowei Ren , Ning Sun , Ying Kong , Yan Li , Jinju Chen , Qianqian Yin , Xiaoling Song , Quanju Zhao , Xing Qiu
IPC: A61K31/675 , A61K31/138 , A61K31/454 , A61K31/496 , A61K31/5025 , A61K31/506 , A61K31/519 , A61K31/5517 , A61K45/06 , A61K47/54 , A61K47/60 , A61P35/00
Abstract: The present disclosure relates to compounds of formula (I) and their anti-tumor uses, and their intermediates of formula (III), intermediates of formula (IV), and uses of the intermediates. The compound of formula (I) has a degrading effect on a specific target protein, which is mainly composed of three parts. The first part is a small molecule compound (SMBP, Small Molecules Binding Protein) that can bind to a protein, the second part LIN is a linker, and the three-part ULM is a ubiquitin ligand (ULM, Ubiquitin Ligase Binding Moiety), wherein SMBP is covalently bound to LIN, and LIN is covalently bound to ULM. A series of compounds designed and synthesized in the present disclosure have a wide range of pharmacological activities, including the functions of degrading specific proteins and/or inhibiting activities of specific proteins, and thus can be used in related tumor treatments.
-
公开(公告)号：US20250064837A1
公开(公告)日：2025-02-27
申请号：US18923448
申请日：2024-10-22
Applicant: ShanghaiTech University
Inventor： Xiaobao Yang , Biao Jiang , Renhong Sun , Chaowei Ren , Ning Sun , Ying Kong , Yan Li , Jinju Chen , Qianqian Yin , Xiaoling Song , Quanju Zhao , Xing Qiu
IPC: A61K31/675 , A61K31/138 , A61K31/454 , A61K31/496 , A61K31/5025 , A61K31/506 , A61K31/519 , A61K31/5517 , A61K45/06 , A61K47/54 , A61K47/60 , A61P35/00
Abstract: The present disclosure relates to compounds of formula (I) and their anti-tumor uses, and their intermediates of formula (III), and uses of the intermediates. The compound of formula (I) has a degrading effect on a specific target protein, which is mainly composed of three parts. The first part is a small molecule compound (SMBP, Small Molecules Binding Protein) that can bind to a protein, the second part LIN is a linker, and the three-part ULM is a ubiquitin ligand (ULM, Ubiquitin Ligase Binding Moiety), wherein SMBP is covalently bound to LIN, and LIN is covalently bound to ULM. A series of compounds designed and synthesized in the present disclosure have a wide range of pharmacological activities, including the functions of degrading specific proteins and/or inhibiting activities of specific proteins, and thus can be used in related tumor treatments.
-
公开(公告)号：US11492645B2
公开(公告)日：2022-11-08
申请号：US17272252
申请日：2019-08-29
Applicant: ShanghaiTech University
Inventor： Jia Liu , Biao Jiang , Peixiang Ma , Guang Yang
IPC: C12N15/63 , A61K31/70 , C12N15/90 , A61K31/7088 , A61K38/16 , A61K38/46 , A61K38/50 , C12N7/00 , A01K67/00
Abstract: Provided are amino acid sequences capable of binding to and inhibiting a Cas protein's ability to bind to a nucleic acid molecule, thereby inhibiting the Cas protein's function in genome editing. Such Cas protein inhibitors, which can be comprised of a major coat protein (G8P), an extracellular region of the G8P (G8PEX), or a biological equivalent, are useful in improving the specificity of Cas protein-based genome editing procedures.
-
9.发明申请公开(公告)号：US20250154146A1
公开(公告)日：2025-05-15
申请号：US18727048
申请日：2023-01-03
Applicant: ShanghaiTech University , Fudan University
Inventor： Xiaobao Yang , Biao Jiang , Wenfu Tan
IPC: C07D471/04 , A61K31/496 , A61K45/06 , A61P35/02 , C07D401/04
Abstract: The present disclosure provides protein degraders developed based on BCL-2 family protein lig and compounds, including compounds of Formula (I) or their salts, enantiomers, stereoisomers, solvates, prodrugs, or polymorphs, and their applications for treating diseases.
-
公开(公告)号：US20250144223A1
公开(公告)日：2025-05-08
申请号：US18689031
申请日：2022-08-25
Inventor： Xiaobao Yang , Gaofeng Fan , Biao Jiang , Haixia Liu , Xiaotong Zhu , Renhong Sun
Abstract: The present disclosure provides compounds of Formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug, or polymorph thereof, and uses thereof. The present disclosure also provides pharmaceutical compositions comprising, as an active ingredient, the compound of Formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug, or polymorph thereof, and uses thereof. The series of compounds designed and synthesized in the present disclosure can effectively prevent and/or treat diseases or disorders associated with NAMPT.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.017 seconds)
